J. Heimbach

Hepatology · 2005–2023

A researcher in the Science corpus: 8 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

Whom J. Heimbach trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Jordi Bruix1 , 2
  2. J. Llovet
  3. Amit G. Singal
  4. C. Lo
  5. M. Sherman

Who trusts J. Heimbach overall

  1. Jorge Marrero
  2. N. Chalasani
  3. L. Kulik

Papers from J. Heimbach's perspective

Ordered by how strongly the researchers J. Heimbach trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. (Gastroenterology)
  2. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. (The Lancet Oncology)
  3. Long-Term Survival and Pattern of Recurrence After Resection of Small Hepatocellular Carcinoma in Patients With Preserved Liver Function: Implications for a Strategy of Salvage Transplantation (Annals of Surgery)
  4. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. (The Lancet)
  5. Prospective Randomized Study of Doxorubicin-Eluting-Bead Embolization in the Treatment of Hepatocellular Carcinoma: Results of the PRECISION V Study (Cardiovascular and Interventional Radiology)
  6. A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria (Annals of Surgery)
  7. The International Position on Laparoscopic Liver Surgery: The Louisville Statement, 2008 (Annals of Surgery)
  8. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data (Hepatology)
  9. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). (European Journal of Cancer)
  10. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. (The Lancet Oncology)

Their papers